Momordica Charantia lectin exhibits antitumor activity towards hepatocellular carcinoma

Investigational New Drugs

Volumn 33, Issue 1, 2015, Pages 1-11

  Zhang, Chris Zhiyi ^a   Fang, Evandro Fei ^b   Zhang, Hai Tao ^c   Liu, Li Li ^a   Yun, Jing Ping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bid; Hepatocellular carcinoma; MCL

Indexed keywords

CASPASE 3; CASPASE 8 INHIBITOR; LECTIN; MITOGEN ACTIVATED PROTEIN KINASE; MOMORDICA CHARANTIA LECTIN; PROTEIN BID; PROTEIN INHIBITOR; SMALL INTERFERING RNA; SORAFENIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BID PROTEIN, HUMAN; PLANT LECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DAMAGE; CELL MEMBRANE DEPOLARIZATION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG POTENTIATION; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MITOCHONDRION; MOMORDICA CHARANTIA; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; LIVER NEOPLASMS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; NUDE MOUSE; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LIVER NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE, NUDE; MOMORDICA CHARANTIA; PLANT LECTINS; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921423079     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0156-8     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101:1348-13553
3. Finn RS (2012) Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition. Liver Cancer 1:247-256
4. Raza A, Sood GK (2014) Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 20:4115-4127
5. Zhou Y, Liu YE, Cao J, Zeng G, Shen C, Li Y, Zhou M, Chen Y, Pu W, Potters L, Shi YE (2009) Vitexins, nature-derived lignan compounds, induce apoptosis and suppress tumor growth. Clin Cancer Res 15:5161-5169
6. Ma YC, Ke Y, Zi X, Zhao W, Shi XJ, Liu HM (2013) Jaridonin, a novel ent-kaurene diterpenoid from Isodon rubescens, inducing apoptosis via production of reactive oxygen species in esophageal cancer cells. Curr Cancer Drug Targets 13:611-624
7. Fang EF, Zhang CZ, Wong JH, Shen JY, Li CH, Ng TB (2012) The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo. Cancer Lett 324:66-74
8. Fang EF, Zhang CZ, Fong WP, Ng TB (2012) RNase MC2: a new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways. Apoptosis 17:377-387
9. Czabotar PE, Lessene G, Strasser A, Adams JM (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15:49-63
10. Llambi F, Moldoveanu T, Tait SW, Bouchier-Hayes L, Temirov J, McCormick LL, Dillon CP, Green DR (2011) A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 44:517-531
11. He K, Zheng X, Zhang L, Yu J (2013) Hsp90 inhibitors promote p53-dependent apoptosis through PUMA and Bax. Mol Cancer Ther 12:2559-2568
12. Zhao Y, Li R, Xia W, Neuzil J, Lu Y, Zhang H, Zhao X, Zhang X, Sun C, Wu K (2010) Bid integrates intrinsic and extrinsic signaling in apoptosis induced by alpha-tocopheryl succinate in human gastric carcinoma cells. Cancer Lett 288:42-49
13. Dong Y, Cao A, Shi J, Yin P, Wang L, Ji G, Xie J, Wu D (2014) Tangeretin, a citrus polymethoxyflavonoid, induces apoptosis of human gastric cancer AGS cells through extrinsic and intrinsic signaling pathways. Oncol Rep 31:1788-1794
14. Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piche A (2010) The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene 29:5523-5536
15. Fang EF, Zhang CZ, Ng TB, Wong JH, Pan WL, Ye XJ, Chan YS, Fong WP (2012) Momordica Charantia lectin, a type II ribosome inactivating protein, exhibits antitumor activity toward human nasopharyngeal carcinoma cells in vitro and in vivo. Cancer Prev Res (Phila) 5:109-121
16. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555-1577
17. Follet J, Corcos L, Baffet G, Ezan F, Morel F, Simon B, Le Jossic-Corcos C (2012) The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis. Br J Cancer 106:685-692
18. Chen JJ, Mikelis CM, Zhang Y, Gutkind JS, Zhang B (2013) TRAIL induces apoptosis in oral squamous carcinoma cells-a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5. Oncotarget 4:206-217
19. Liu GY, Liao YF, Hsu PC, Chang WH, Hsieh MC, Lin CY, Hour TC, Kao MC, Tsay GJ, Hung HC (2006) Antizyme, a natural ornithine decarboxylase inhibitor, induces apoptosis of haematopoietic cells through mitochondrial membrane depolarization and caspases' cascade. Apoptosis 11:1773-1788
20. Kavitha K, Kowshik J, Kishore TK, Baba AB, Nagini S (2013) Astaxanthin inhibits NF-kappaB and Wnt/beta-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochim Biophys Acta 1830:4433-4444
21. Lien SC, Chang SF, Lee PL, Wei SY, Chang MD, Chang JY, Chiu JJ (2013) Mechanical regulation of cancer cell apoptosis and autophagy: roles of bone morphogenetic protein receptor, Smad1/5, and p38 MAPK. Biochim Biophys Acta 1833:3124-3133
22. Zhuang S, Demirs JT, Kochevar IE (2000) p38 mitogen-activated protein kinase mediates bid cleavage, mitochondrial dysfunction, and caspase-3 activation during apoptosis induced by singlet oxygen but not by hydrogen peroxide. J Biol Chem 275:25939-25948
23. Kang SJ, Kim BM, Lee YJ, Hong SH, Chung HW (2009) Titanium dioxide nanoparticles induce apoptosis through the JNK/p38-caspase-8-Bid pathway in phytohemagglutinin-stimulated human lymphocytes. Biochem Biophys Res Commun 386:682-687
24. Dong Y, Xiong M, Duan L, Liu Z, Niu T, Luo Y, Wu X, Xu C, and Lu C (2014) H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib. Apoptosis
25. Pei D, Zhang Y, Zheng J (2012) Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget 3:228-235
26. Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R, Adams PD, Anderson KI, Gottlieb E, Sansom OJ, Ryan KM (2013) p53 status determines the role of autophagy in pancreatic tumour development. Nature 504:296-300
27. Printz C (2009) Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer 115:4646
28. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379:1245-1255
29. Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW, Chen PJ, Chen KF (2012) Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Mol Cancer Ther 11:452-463